2025-06-12-Jefferies-科迪华（CTVA）_作物化学品销量可能抵消价格疲软_种子前景稳固_9页_199kb

Corteva is rated "Buy" with a 12-month price target of $92, implying a 27% upside from the current price and a valuation multiple of approximately 24.9x estimated earnings per share for 2027. The outlook favors Corteva due to a likely cyclical rebound in agriculture, with expected growth in crop protection and seed volumes supporting a 3% sales compound annual growth rate through 2027. Price headwinds from tariffs and currency fluctuations are projected to be lower than previously anticipated, with estimated savings reducing from $50 million to $25–$30 million for tariffs and limiting currency impact to under $200 million. Key drivers include volume increases from late harvest effects in North America, heightened Brazilian corn acreage, and Argentinian recovery, coupled with mix improvements and over $400 million in cost reductions expected to expand EBITDA margins by up to 320 basis points over the period. Long-term catalysts involve gene editing technology, operating leverage from climate stress in seed pricing, and M&A potential, while risks noted include ag cycle volatility and erosion of R&D productivity. The company trades at a forward EV/EBITDA multiple of 12.6x, above its five-year average, and is positioned to benefit from sustainable growth through innovations in product design and digital solutions.